MA27330A1 - Arylcycloalkylamines acylees et leur utilisation en tant que produits pharmaceutiques - Google Patents
Arylcycloalkylamines acylees et leur utilisation en tant que produits pharmaceutiquesInfo
- Publication number
- MA27330A1 MA27330A1 MA28082A MA28082A MA27330A1 MA 27330 A1 MA27330 A1 MA 27330A1 MA 28082 A MA28082 A MA 28082A MA 28082 A MA28082 A MA 28082A MA 27330 A1 MA27330 A1 MA 27330A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- formula
- arylcycloalkylamines
- relates
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La présente invention concerne des arylcycloalkylamines de formule I, dans laquelle RI, R2 et n sont tels que décrits dans les revendications. Les composés de formule I constituent des composés actifs pharmacologiquement précieux qui sont utiles dans le traitement de différentes pathologies, notamment, de troubles cardio-vasculaires, tels que l'athérosclérose, la thrombose, la maladie coronarienne, l'hypertension et l'insuffisance cardiaque. Lesdits composés régulent positivement l'expression de l'enzyme oxyde nitrique (NO) synthase endothéliale et peuvent être utilisés pour des pathologies dans lesquelles une expression accrue de ladite enzyme ou un niveau de NO accru ou la normalisation d'un niveau de NO abaissé est souhaitée. L'invention concerne également des procédés de préparation des composés de formule I, leur utilisation, notamment en tant que principes actifs dans des agents pharmaceutiques, ainsi que des préparations pharmaceutiques les comprenant.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02017587A EP1388535A1 (fr) | 2002-08-07 | 2002-08-07 | Arylcycloalkylamines acylés et leurs utilisations comme produits pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27330A1 true MA27330A1 (fr) | 2005-05-02 |
Family
ID=30129195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28082A MA27330A1 (fr) | 2002-08-07 | 2005-02-01 | Arylcycloalkylamines acylees et leur utilisation en tant que produits pharmaceutiques |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP1388535A1 (fr) |
JP (1) | JP4555683B2 (fr) |
KR (1) | KR101080627B1 (fr) |
CN (1) | CN1304365C (fr) |
AR (1) | AR040791A1 (fr) |
AU (1) | AU2003250159B2 (fr) |
BR (1) | BR0313271A (fr) |
CA (1) | CA2494628C (fr) |
HK (1) | HK1079186A1 (fr) |
HR (1) | HRP20050118A2 (fr) |
IL (1) | IL166491A (fr) |
MA (1) | MA27330A1 (fr) |
ME (1) | MEP60508A (fr) |
MX (1) | MXPA05001371A (fr) |
MY (1) | MY141885A (fr) |
NO (1) | NO332654B1 (fr) |
NZ (1) | NZ538089A (fr) |
PL (1) | PL210930B1 (fr) |
RS (1) | RS20050098A (fr) |
RU (1) | RU2337094C2 (fr) |
TW (1) | TWI317732B (fr) |
WO (1) | WO2004014842A1 (fr) |
ZA (1) | ZA200410273B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097751A2 (fr) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Composes heterocycliques non-imidazole |
EP1741708A1 (fr) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique |
EP1741709A1 (fr) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Amides heterocycliques substitués contenant un linker saturé, et leur utilisation comme agent pharmaceutique |
KR20110007258A (ko) | 2006-03-22 | 2011-01-21 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd-1로서의 피라졸 |
WO2007134799A1 (fr) * | 2006-05-18 | 2007-11-29 | Syngenta Participations Ag | Nouveaux microbiocides |
MX2008015365A (es) | 2006-05-30 | 2008-12-16 | Janssen Pharmaceutica Nv | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
ES2300223B1 (es) * | 2006-07-07 | 2009-09-11 | Universidad De Granada | 3-benzoilpirazoles inhibidores de la oxido nitrico sintasa (nos) con actividad neuroprotectora. |
EP1905764A1 (fr) * | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | 2-Phenylbenzimidazoles et leur utilisation comme composés pharmaceutiques |
EP1923062A1 (fr) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles et leur utilisation comme agent pharmaceutique |
EP1939180A1 (fr) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
EP1942104A1 (fr) * | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
EP1939181A1 (fr) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase |
EP1964841A1 (fr) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine et son utilisation en tant que produit pharmaceutique |
EP1964840A1 (fr) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines et leur utilisation en tant que produits pharmaceutiques |
EP2207540B1 (fr) | 2007-10-04 | 2014-02-26 | F. Hoffmann-La Roche AG | Dérivés de cyclopropyl aryl amides et leurs utilisations |
AU2008326561B2 (en) | 2007-11-20 | 2013-12-05 | Janssen Pharmaceutica N.V. | Cycloalkyloxy-and heterocycloalky-loxypyridine compounds as modulators of the histamine H3 receptor |
WO2009152356A2 (fr) * | 2008-06-11 | 2009-12-17 | Irm Llc | Composés et compositions utiles pour le traitement de la malaria |
US20140329833A1 (en) * | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
EP2750671A2 (fr) * | 2011-05-19 | 2014-07-09 | Oryzon Genomics, S.A. | Inhibiteurs de la lysine déméthylase destinés au traitement de la thrombose et de maladies cardiovasculaires |
MX339433B (es) * | 2011-07-26 | 2016-05-26 | Sanofi Sa | Derivados de acido 3 - tiazoloamino - propionico sustituidos y su uso como sustancias farmaceuticas. |
ITMI20111971A1 (it) * | 2011-10-28 | 2013-04-29 | Mesogenics Srl | Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico |
BR112014019622B8 (pt) | 2012-02-14 | 2020-05-26 | Syngenta Participations Ag | composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas |
EP2644595A1 (fr) | 2012-03-26 | 2013-10-02 | Syngenta Participations AG. | N-cyclylamides comme nematicides |
UY35543A (es) * | 2013-04-30 | 2014-11-28 | Bayer Cropscience Ag | N-(fenilcicloalquil)carboxamidas y n-(fenilcicloalquil)tiocarboxamidas nematicidas |
CA2917264C (fr) * | 2013-07-08 | 2020-08-18 | Syngenta Participations Ag | Carboxamides presentant des cycles a 4 chainons utilises comme nematicides |
WO2015040141A1 (fr) | 2013-09-23 | 2015-03-26 | Syngenta Participations Ag | Cyclobutylcarboxamides en tant que nématicides |
WO2015175487A1 (fr) | 2014-05-13 | 2015-11-19 | Novartis Ag | Composés et compositions d'induction de la chondrogenèse |
US20200087271A1 (en) | 2016-12-20 | 2020-03-19 | Syngenta Participations Ag | N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity |
EP3976601B1 (fr) * | 2019-05-29 | 2024-02-28 | Syngenta Crop Protection AG | Dérivés microbiocides |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3192229A (en) * | 1962-07-03 | 1965-06-29 | Colgate Palmolive Co | Phenylcyclopropyl amides |
US4625040A (en) * | 1984-09-24 | 1986-11-25 | Pennwalt Corporation | N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives |
US4614810A (en) * | 1984-09-24 | 1986-09-30 | Pennwalt Corporation | 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof |
IL84944A (en) * | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
CZ287969B6 (cs) * | 1995-08-10 | 2001-03-14 | Astra Pharmaceuticals Limited | Amidinový derivát, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a použití |
JP3844533B2 (ja) * | 1995-12-15 | 2006-11-15 | 日本曹達株式会社 | 2,6−ジクロロイソニコチン酸フェネチルアミド誘導体及び植物病害防除剤 |
US5945431A (en) * | 1996-03-15 | 1999-08-31 | Biochem Therapeutics Incorporated | Cytomegalovirus inhibiting compounds |
US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
CN1283995A (zh) * | 1997-12-11 | 2001-02-14 | 生化制药有限公司 | 抗病毒化合物 |
ATE292465T1 (de) * | 1998-05-22 | 2005-04-15 | Avanir Pharmaceuticals | Benzimidazol-derivate als ige-modulatoren |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
KR100676987B1 (ko) * | 1998-11-04 | 2007-01-31 | 메이지 세이카 가부시키가이샤 | 피콜린산아미드 유도체, 그 것을 유효성분으로서 함유하는유해생물 방제제 |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
ATE430745T1 (de) * | 2000-10-12 | 2009-05-15 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
PT1368028E (pt) * | 2001-03-12 | 2007-11-26 | Avanir Pharmaceuticals | Compostos de benzimidazole para modulação de ige e inibição da proliferação celular |
DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
ATE455104T1 (de) * | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
-
2002
- 2002-08-07 EP EP02017587A patent/EP1388535A1/fr not_active Withdrawn
-
2003
- 2003-07-24 RS YUP-2005/0098A patent/RS20050098A/sr unknown
- 2003-07-24 MX MXPA05001371A patent/MXPA05001371A/es active IP Right Grant
- 2003-07-24 PL PL373068A patent/PL210930B1/pl not_active IP Right Cessation
- 2003-07-24 NZ NZ538089A patent/NZ538089A/en not_active IP Right Cessation
- 2003-07-24 WO PCT/EP2003/008104 patent/WO2004014842A1/fr active Application Filing
- 2003-07-24 RU RU2005106256/04A patent/RU2337094C2/ru not_active IP Right Cessation
- 2003-07-24 CA CA2494628A patent/CA2494628C/fr not_active Expired - Fee Related
- 2003-07-24 AU AU2003250159A patent/AU2003250159B2/en not_active Ceased
- 2003-07-24 JP JP2004526766A patent/JP4555683B2/ja not_active Expired - Fee Related
- 2003-07-24 KR KR1020057002078A patent/KR101080627B1/ko not_active IP Right Cessation
- 2003-07-24 CN CNB038191237A patent/CN1304365C/zh not_active Expired - Fee Related
- 2003-07-24 EP EP03784056A patent/EP1529031A1/fr not_active Withdrawn
- 2003-07-24 ME MEP-605/08A patent/MEP60508A/xx unknown
- 2003-07-24 BR BR0313271-4A patent/BR0313271A/pt not_active IP Right Cessation
- 2003-08-05 AR AR20030102804A patent/AR040791A1/es unknown
- 2003-08-05 TW TW092121313A patent/TWI317732B/zh not_active IP Right Cessation
- 2003-08-06 MY MYPI20032960A patent/MY141885A/en unknown
-
2004
- 2004-12-21 ZA ZA200410273A patent/ZA200410273B/en unknown
-
2005
- 2005-01-25 IL IL166491A patent/IL166491A/en not_active IP Right Cessation
- 2005-02-01 MA MA28082A patent/MA27330A1/fr unknown
- 2005-02-04 HR HR20050118A patent/HRP20050118A2/xx not_active Application Discontinuation
- 2005-03-01 NO NO20051110A patent/NO332654B1/no not_active IP Right Cessation
- 2005-12-06 HK HK05111109A patent/HK1079186A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2003250159B2 (en) | 2009-12-24 |
KR101080627B1 (ko) | 2011-11-08 |
IL166491A0 (en) | 2006-01-15 |
IL166491A (en) | 2010-06-30 |
JP2005534706A (ja) | 2005-11-17 |
HRP20050118A2 (en) | 2005-10-31 |
EP1529031A1 (fr) | 2005-05-11 |
NZ538089A (en) | 2006-09-29 |
RU2337094C2 (ru) | 2008-10-27 |
BR0313271A (pt) | 2005-06-21 |
JP4555683B2 (ja) | 2010-10-06 |
WO2004014842A8 (fr) | 2005-04-28 |
TW200410919A (en) | 2004-07-01 |
NO20051110L (no) | 2005-03-01 |
CN1304365C (zh) | 2007-03-14 |
CA2494628A1 (fr) | 2004-02-19 |
PL210930B1 (pl) | 2012-03-30 |
ZA200410273B (en) | 2006-07-26 |
AU2003250159A1 (en) | 2004-02-25 |
MXPA05001371A (es) | 2005-04-28 |
KR20060002725A (ko) | 2006-01-09 |
HK1079186A1 (en) | 2006-03-31 |
RU2005106256A (ru) | 2005-08-10 |
MY141885A (en) | 2010-07-16 |
EP1388535A1 (fr) | 2004-02-11 |
MEP60508A (en) | 2011-05-10 |
CA2494628C (fr) | 2011-12-13 |
TWI317732B (en) | 2009-12-01 |
CN1675170A (zh) | 2005-09-28 |
PL373068A1 (en) | 2005-08-08 |
WO2004014842A1 (fr) | 2004-02-19 |
AR040791A1 (es) | 2005-04-20 |
NO332654B1 (no) | 2012-11-26 |
RS20050098A (en) | 2007-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27330A1 (fr) | Arylcycloalkylamines acylees et leur utilisation en tant que produits pharmaceutiques | |
MA27331A1 (fr) | Cycloalcenylamines heteroaryl-condensees et acylees, et leur utilisation en tant que produits pharmaceutiques | |
TNSN05037A1 (fr) | Derives heterobiaryliques servant d'inhibiteurs de metalloproteinases de matrice | |
Bernhardt et al. | Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD | |
Brown et al. | Potent and selective mechanism-based inhibition of gelatinases | |
US6890925B2 (en) | Methods of using soluble epoxide hydrolase inhibitors | |
MA29693B1 (fr) | Derives de xanthine en tant qu'agonistes hm74a selectifs | |
TNSN07476A1 (fr) | Derives de n-(pyridine -2- yl) - sulfonamide | |
MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
HUE028129T2 (en) | New preparations for the prevention and / or treatment of lysosomal storage disorders | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
TNSN03130A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
MA28072A1 (fr) | Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie | |
CA2392165A1 (fr) | Analogues de la vitamine d | |
CN102448306A (zh) | 用于预防和/或治疗中枢神经系统退行性紊乱的方法 | |
TNSN99024A1 (fr) | Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque | |
MA29723B1 (fr) | Composes | |
CN1390122A (zh) | 组织因子拮抗剂及其使用方法 | |
US6593362B2 (en) | Non-peptidic cyclophilin binding compounds and their use | |
TW201622728A (zh) | 全身紅斑性狼瘡之治療 | |
HUP9802663A2 (hu) | Szénhidrátszármazékok és ezeket tartalmazó gyógyászati készítmények | |
Bebawi et al. | A metoprolol–terbinafine combination induced bradycardia | |
MA27798A1 (fr) | DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa |